Pubmed logo      Google Scholar

Maroon text and star () denotes members of the Blattman Laboratory at Arizona State University.

Purple text and star () denotes members of the Blattman/Greenberg Laboratory at the University of Washington.

Total citations for Blattman, JN:6817,  h-index:26,  m-quotient:1.41,  i10-index:32


  1. Franco LS, Mujica V, Blattman JN, §Garcia AA, (2016) Successive Optimization of Homogeneous Immunoassays Using Gold Nanoparticles for Antibody Detection, PLoS One (in press).
  2. Holechek SA, McAfee MS, Nieves L, Guzman V, Manhas K, Bagley K, Fouts T, §Blattman JN (2016) DNA Vaccination with Retinaldehyde Dehydrogenase 2 as a Molecular Adjuvant for Enhancement of Mucosal CD8 T Cell Immunity During DNA Vaccination, Vaccine 34(43):5629-5635.
  3. Lussier DM~, Woolf EC~, Johnson JL, Brooks KS, Blattman JN, §Scheck AC (2016) Enhanced Immunity in a Model of Malignant Glioma is Mediated by a Therapeutic Ketogenic Diet, BMC Cancer 16:310.


  1. McAfee MS, Hungh T, Johnson JL, Jacobs BJ, §Blattman JN (2015) Interaction Between Unrelated Viruses during Co-infection to Limit Pathology and Immunity, Virology 484:153-162.
  2. Lussier DM, Johnson JL, Hingorani P, §Blattman JN (2015) Combination Immunotherapy with α-CTLA4 and α-PD-L1 Antibody Blockade Prevents Immune Escape and Leads to Complete Control of Metastatic Osteosarcoma, J ImmunoTher Cancer 3:21.
  3. Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X, Greenberg PD, §§Klavinskis LS, §§Blattman JN, §§Anderson KS (2015) TCR Contact Residue Hydrophobicity is a Hallmark of Immunogenic CD8+ T Cell Epitopes, Proc Natl Acad Sci (USA) 112(14):E1754-1762.
  4. Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, §Blattman JN (2015) Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions, J Immunother 38(3):96-106.


Blattman NN, Lagunoff M, Blattman JN, §Corey L (2014) Nuclear Factor Kappa B is Required for the Production of Infectious Human Herpesvirus 8 Virions, Front Microbiol 5:129.


  1. Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, §Antia R (2013) Estimating the Completeness, Redundancy and Cross-Reactivity of the T Cell Repertoire, Front Immunol 4:485.
  2. Demidenko AA, Blattman JN, Blattman NN, Greenberg PD, §Nibert ML (2013) Engineering Recombinant Reoviruses with Tandem Repeats and a Tetravirus 2A-like Element for Exogenous Polypeptide Expression, Proc Nat Acad Sci (USA) 110(20):E1867-76.


  1. Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok W-L, Cole S, Ho L-P, Lambe T, Puthia M, Svanborg C, Scherer EM, Krashias G, Williams A, Blattman JN, Greenberg PD, Flavell R, Moghaddam A, §§Sheppard NC, §§Sattentau QJ (2012) Polyethyleneimine is a Potent Mucosal Adjuvant for Viral Glycoprotein Antigens, Nat Biotech 30(9):883-888.
  2. Stromnes IM, Fowler CC, Blattman JN, Georgopolos C, McAfee MS, Tan X, §Greenberg PD (2012) Abrogation of Src Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo, J Immunol 189(4):1812-1825.
  3. Schietinger A, Delrow JJ, Basom RS, Blattman JN, §Greenberg PD (2012) Rescued Tolerant CD8 T cells are Preprogrammed to Reestablish the Tolerant State, Science 335(6069):723-727.


  1. Tan X, Sande JL, Pufnock JS, §§Blattman JN, §§Greenberg PD (2011) Use of Retinoic Acid as an Adjuvant to Imprint Mucosal Homing Properties to Vaccine-Induced T Cells, J Virol 85(16):8316-8327.
  2. Johnson PLF, Kochin BF, McAfee MS, Stromnes IM, Regoes RR, Ahmed R, Blattman JN, §Antia R (2011) Vaccination Alters the Balance between Protective Immunity, Exhaustion, and Pathology Following Disseminated Viremia, J Virol 85(11):5565-5570.
  3. Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, Lynch DM, LaPorte A, Simmons NL, Clark SL, Pulendran B, Greenberg PD, §Barouch DH (2011) Multiple Redundant Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenoviral Vectors, J Virol 85(1):315-323.


  1. ~Stromnes IM, ~Blattman JN, Tan X, Jeevanjee S, Gu H, §Greenberg PD (2010) Abrogating Cbl-b- in Effector CD8(+) T Cells Improves the Efficacy of Adoptive Therapy of Leukemia in Mice, J Clin Inv 120(10):3722-3734.
  2. Fowler CC, Pao L, §§Greenberg PD, §§Blattman JN (2010) SHP-1 in T Cells Limits the Production of CD8 Effector Cells Without Impacting the Formation of Long-lived Central Memory Cells, J Immunol 185(6):3256-3267.


Blattman JN, Wherry EJ, Ha SJ, van der Most RG, §Ahmed R (2009) The Impact of Epitope Escape on PD-1 Expression and CD8 T Cell Exhaustion During Chronic Infection, J Virol 83(9):4386-4394.


  1. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, §Ahmed R (2007) Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection, Immunity 27(4):670-684.
  2. Shin H, Blackburn S, Blattman JN, §Wherry EJ (2007) Viral Antigen and Extensive Division Maintain Virus-Specific CD8 T Cells During Chronic Infection, J Exp Med 204(4):941-949.


Wherry, EJ, Blattman JN, §Ahmed R (2005) Low CD8 T-cell Proliferative Potential and High Viral Load Limit the Effectiveness of Therapeutic Vaccination, J Virol 79(14):8960-8968.


  1. Wherry EJ, Barber DL, Kaech SM, Blattman JN, §Ahmed R (2004) Antigen-Independent Memory CD8 T Cells do not Develop during Chronic Viral Infection, Proc Nat Acad Sci USA 101(45):16004-16009.
  2. Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, Wang Y, Davis RJ, Greenberg PD, Flavell RA, §Dong C (2004) Regulation of Innate and Adaptive Immune Responses by MAP Kinase Phosphatase 5, Nature 430(7001):793-797.


  1. van der Most RG, Murali-Krishna K, Lanier JG, Wherry EJ, Puglielli MT, Blattman JN, Zajac AJ, Sette AD, §Ahmed R (2003) Changing Immunodominance Patterns in Antiviral CD8 T cell Responses after Loss of Epitope Presentation or Chronic Antigen Stimulation, Virology 315(1):93-102.
  2. Topp M, Riddell S, Akatsuka Y, Jensen MC, Blattman JN, §Greenberg PD (2003) Restoration of CD28 Expression in CD28-CD8+ Memory Effector T-cells Reconstitutes Antigen-Induced IL-2 Production, Brief Definitive Report, J Exp Med 198(6):947-955.
  3. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, §Ahmed R (2003) Therapeutic Use of IL-2 to Enhance Antiviral T-cell Responses In Vivo, Nat Med 9(5):540-547.
  4. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most RG, §Ahmed R (2003) Viral Persistence Alters CD8 T-cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment, J Virol 77(8):4911-4927.
  5. Seiffert M, Custodio JM, Wolf I, Harkey M, Liu Y, Blattman JN, Greenberg PD, §Rohrscneider LR (2003) Gab3-Deficient Mice Exhibit Normal Development and Hematopoiesis and are Immunocompetent, Mol Cell Biol 23(7):2415-2424.
  6. Slifka MK, Blattman JN, Sourdive DJD, Liu F, Huffman DL, Wolfe T, Hughes A, Oldstone MBA, Ahmed R, §von Herrath MG (2003) Preferential Escape of Subdominant CD8+ T cells during Negative Selection Results in an Altered Antiviral T cell Hierarchy, J Immunol 170(3):1231-1239.


Blattman JN, Antia R, Sourdive DJD, Murali-Krishna K, Wang X, Kaech SM, Altman JD, §Ahmed R (2002) Estimating the Precursor Frequency of Naïve Antigen-Specific CD8+ T Cells, Brief Definitive Report, J Exp Med 195(5):657-664.


Blattman JN, Sourdive DJD, Murali-Krishna K, Ahmed R, §Altman JD (2000) Evolution of the T Cell Repertoire during Primary, Memory, and Recall Responses to Viral Infection, J Immunol 165(11):6081-6090.


Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJD, Suresh M, Altman JD, §Ahmed R (1998) Viral Immune Evasion due to Persistence of Activated T Cells Without Effector Function, J Exp Med 188(12):2205-2213.

Invited Review Articles/Book Chapters

  1. Lussier DM, Appel N, §Blattman JN (2016) Immune Checkpoint Blockade in Osteosarcoma in “Osteosarcoma – Biology, Behavior and Mechanisms”, K. Honoki ed, InTech Open Publishers, ISBN 978-953-51-4915-6 (in press).
  2. Lettieri C, Lussier DM, Appel N, Labban N, Blattman JN, §Hingorani P (2016) Progress and Opportunities for Immune Therapeutics in Osteosarcoma, Immunotherapy 8(10):1233-1244.
  3. Schoettle LN, Poindexter ME, §Blattman JN (2015) T Cell Receptors, Encyclopedia of Life Sciences, John Wiley & Sons.           
  4. McAfee MS, §Blattman JN (2012) Combating Chronic T Cell Exhaustion, Immunotherapy 4(6):567-560.
  5. Blattman JN, §Greenberg PD (2006) PD-1 Blockade: Rescue from a Near-Death Experience, Nat Immunol 7(3):227-228.
  6. Blattman JN, §Greenberg PD (2004) Cancer Immunotherapy: A Treatment for the Masses, Science 305(5681):200-205.
  7. Ho WY, Blattman JN, Dossett M, Yee C, §Greenberg PD (2003) Adoptive Immunotherapy: Engineering T Cell Responses as Biologic Weapons for Tumor Mass Destruction, Cancer Cell 3(5):431-437.
  8. Blattman JN, Cheng LE, §Greenberg PD (2002) CD8+ T cell responses: It’s all downhill after their prime…, Nat Immunol 3(7):601-602.
  9. Blattman JN~, Zajac AJ~, Murali-Krishna K, Sourdive DJD, Suresh M, Altman JD, §Ahmed R (1999) T Cell Anergy During Chronic Viral Infection in “Factors in the Emergence and Control of Rodent-borne Diseases (Hantaviral and Arenal Diseases)”, J.F. Saluzzo and B. Dodet, ed., Elsevier, Paris, pp. 243-253.
  10. Zajac AJ, Murali-Krishna K, Blattman JN, §Ahmed R (1998) Therapeutic Vaccination Against Chronic Viral Infection: The Importance of Cooperation Between CD4+ and CD8+ T Cells, Curr Opin Immunol 10(4):444-449.